Jefferies analyst Scott A. Mushkin said in another note he was "strongly reiterating" his "Buy" rating on the stock. He said implementation of the health care overhaul could lead to more customers and higher-than-expected earnings per share growth for the company.
While there remains a tremendous amount of uncertainty around the implications of (the overhaul), what is becoming increasingly evident to us is that CVS Caremark has the potential to capture greater market share and see a jump in covered lives," the analyst wrote.
Credit Suisse analyst Edward J. Kelly raised his price target on the stock to $55 from $50. He wrote in separate research note that the company's 2013 guidance was surprising, and it fueled a story that looked like it was "running out of gas in 2013."